List of SBIR/STTR awards granted to Glycan Therapeutics
Glycan TherapeuticsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to Glycan Therapeutics in March, 2020 for $1,229,662.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44GM134738-02 | Phase II | 1,229,662 | March 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in August, 2019 for $536,791.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44GM134738-01 | Phase I | 536,791 | August 1, 2019 | |||||||
A STTR Phase II contract was awarded to Glycan Therapeutics in December, 2018 for $743,671.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42GM128484-02 | Phase II | 743,671 | December 1, 2018 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in September, 2021 for $231,139.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM144019-01 | Phase I | 231,139 | September 14, 2021 | |||||||
A STTR Phase I contract was awarded to Glycan Therapeutics in May, 2018 for $334,239.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42GM128484-01 | Phase I | 334,239 | May 1, 2018 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in September, 2021 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM142304-01 | Phase I | 300,000 | September 15, 2021 | |||||||
A SBIR Phase II contract was awarded to Glycan Therapeutics in July, 2019 for $1,244,412.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44HL139187-02 | Phase II | 1,244,412 | July 4, 2019 | |||||||
A SBIR Phase II contract was awarded to Glycan Therapeutics in September, 2022 for $988,771.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44GM142304-02 | Phase II | 988,771 | September 17, 2022 | |||||||
A SBIR Phase II contract was awarded to Glycan Therapeutics in May, 2020 for $1,443,680.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44GM123792-03 | Phase II | 1,443,680 | May 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in May, 2022 for $331,634.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM140693-01A1 | Phase I | 331,634 | May 1, 2022 | |||||||
A STTR Phase I contract was awarded to Glycan Therapeutics in September, 2017 for $296,746.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41GM123792-01A1 | Phase I | 296,746 | September 1, 2017 | |||||||
A STTR Phase I contract was awarded to Glycan Therapeutics in August, 2017 for $224,698.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41HL139187-01 | Phase I | 224,698 | August 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Glycan Therapeutics for $693,710.0 USD from the U.S. Department of Health & Human Services. | SBIR | 261201500019C-5-0-0 | Phase II | 693,710 | ||||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics for $299,447.0 USD from the U.S. Department of Health & Human Services. | SBIR | N43CA130050 | Phase I | 299,447 | ||||||||
A STTR Phase I contract was awarded to Glycan Therapeutics in July, 2023 for $400,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41CA285005-01 | Phase I | 400,000 | July 1, 2023 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in August, 2023 for $355,989.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44GM148100-01A1 | Phase I | 355,989 | August 16, 2023 | |||||||
A SBIR Phase II contract was awarded to Glycan Therapeutics in September, 2023 for $874,308.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44GM144019-02 | Phase II | 874,308 | September 6, 2023 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in September, 2023 for $255,001.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44GM145004-01A1 | Phase I | 255,001 | September 21, 2023 | |||||||
A STTR Phase I contract was awarded to Glycan Therapeutics in September, 2023 for $347,537.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41DE032276-01A1 | Phase I | 347,537 | September 1, 2023 | |||||||
A SBIR Phase I contract was awarded to Glycan Therapeutics in February, 2023 for $350,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM149008-01 | Phase I | 350,000 | February 1, 2023 |
